Trial | NCT01465399  Report issue

Title

Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-Extraction Sockets
Randomized Clinical Trial, Controlled With Conventional Treatment, of Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-extraction Sockets in Simple Extractions of Molars in the Mandible

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    60
Immediately following tooth removal, a healing process begins that affects the eventual alveolar bone volume and architecture of the alveolar ridge. Satisfactory and timely healing are essential to obtain ideal functional reconstruction. Traumatic removal of a tooth, or a poor healing response, may lead to excessive bone loss delaying tooth replacement, requiring expensive and time-consuming reconstructive surgeries, or even the inability to be corrected. The Plasma Rich in Growth Factors (PRGF-Endoret) has shown its therapeutic potential effect to minimize the consequences of this aggression, promoting the regeneration of both hard and soft involved tissues.
Study Started
Oct 31
2011
Primary Completion
Dec 31
2012
Study Completion
Dec 31
2012
Last Update
Aug 23
2021

Biological Plasma Rich in Growth Factors PRGF-Endoret

Procedure Conventional closure of the lesion

PRGF-Endoret Experimental

Conventional treatment Active Comparator

Criteria 

Inclusion Criteria:

subjects of both genders and ≥ 18 years old
Indication of a simple one molar extraction in the mandible.
Possibility of observation during the follow-up period.

Exclusion Criteria:

Unerupted third molars or with horizontal inclination.
Severe swelling prior to surgery in the areas designated for extraction.
Suffering an alteration or a serious hematologic disease.
Be currently undergoing or have received radiotherapy, chemotherapy or immunosuppressive therapy, corticosteroids and/or anticoagulants 30 days prior to inclusion
In regular treatment with NSAIDs or other anti-inflammatory drugs.
History of chronic hepatitis or cirrhosis.
Diabetes mellitus with poor metabolic control (glycosylated hemoglobin >9%)
Patients undergoing dialysis.
Presence of malignant tumors, hemangiomas or angiomas in the extraction area.
History of ischemic heart disease in the last year.
Pregnancy or planned pregnancy during the study follow-up period.
Metabolic Bone Disease.
Patients taking bisphosphonates both orally and intravenously.
In general, any inability to participate in the study.
No Results Posted